Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.19, Zacks reports.
Oruka Therapeutics Stock Up 4.6 %
NASDAQ ORKA traded up $0.48 on Monday, reaching $10.94. The company had a trading volume of 225,467 shares, compared to its average volume of 209,528. Oruka Therapeutics has a 1 year low of $9.44 and a 1 year high of $31.13. The firm has a market capitalization of $382.89 million, a price-to-earnings ratio of -1.75 and a beta of 0.67. The firm's 50-day moving average is $13.26.
Insider Buying and Selling at Oruka Therapeutics
In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the business's stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the acquisition, the insider now owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. This represents a 2.19 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired a total of 98,339 shares of company stock valued at $1,128,456 in the last three months. Corporate insiders own 22.67% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on ORKA shares. HC Wainwright restated a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday. Finally, Wolfe Research assumed coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price target for the company. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Oruka Therapeutics currently has an average rating of "Buy" and an average price target of $39.86.
Check Out Our Latest Research Report on Oruka Therapeutics
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
